Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Advances in the Clinical Management of Genitourinary Tumors
share announcement

Advances in the Clinical Management of Genitourinary Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 1615

Special Issue Editors

Dr. Felix Busch

E-Mail Website
Guest Editor
1. Department of Radiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany
2. School of Medicine, Klinikum Rechts der Isar, Technical University Munich, Ismaninger Straße 22, 81675 Munich, Germany
Interests: genitourinary tumors; radiology; artificial intelligence; deep learning
Dr. Markus Graf

E-Mail Website
Guest Editor
Institute of Diagnostic and Interventional Radiology, School of Medicine, Klinikum Rechts der Isar, Technical University Munich, Ismaninger Straße 22, 81675 Munich, Germany
Interests: artificial intelligence; oncology; imaging biomarkers; interventional radiology

Special Issue Information

Dear Colleagues,

The field of genitourinary cancer management has witnessed remarkable advancements over recent years, driven by breakthroughs in molecular biology, imaging, surgical techniques, systemic therapies, and personalized medicine. These innovations have significantly improved patient outcomes while raising new questions about optimizing care pathways.

This Special Issue aims to provide comprehensive insights into the current state and future directions in the clinical management of renal cell carcinoma, ureteral carcinoma, urethral carcinoma, prostatic carcinoma, bladder carcinoma, and testicular malignancies. Topics of interest include, but are not limited to, the following:

  • Advances in diagnostic imaging and biomarkers for early detection and risk stratification.
  • Emerging surgical and minimally invasive techniques.
  • Innovations in systemic therapies, including immunotherapy, targeted therapy, and hormonal therapy.
  • Optimizing multimodal treatment approaches for localized and metastatic disease.
  • Addressing survivorship, quality of life, and long-term management challenges.
  • The role of artificial intelligence in the clinical management of genitourinary tumors.

For this Special Issue of Cancers, we welcome original research and review articles that provide an overview of the most recent advances and future challenges for the clinical management of genitourinary tumors.

Dr. Felix Busch
Dr. Markus Graf
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urogenital neoplasms
  • prostatic neoplasms
  • kidney neoplasms
  • ureteral neoplasms
  • urethral neoplasms
  • testicular neoplasms
  • urinary bladder neoplasms
  • disease management
  • artificial intelligence
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 437 KiB  
Article
Rectal Injury During Radical Prostatectomy: Incidence, Management, and Outcomes in Single-Center Experience
by Anil Erdik, Haci Ibrahim Cimen, Deniz Gul, Yavuz Tarik Atik, Yasir Muhammed Akca, Fikret Halis, Osman Kose and Hasan Salih Saglam
Cancers 2025, 17(7), 1129; https://doi.org/10.3390/cancers17071129 - 27 Mar 2025
Viewed by 1013
Abstract
Background: Rectal injury (RI) is a rare yet serious complication of radical prostatectomy (RP). In this study, we aimed to assess the incidence, risk factors, management strategies, and outcomes of RI during RP. Methods: A retrospective analysis was conducted on 382 [...] Read more.
Background: Rectal injury (RI) is a rare yet serious complication of radical prostatectomy (RP). In this study, we aimed to assess the incidence, risk factors, management strategies, and outcomes of RI during RP. Methods: A retrospective analysis was conducted on 382 patients who underwent RP between 2012 and 2024. Cases of RI were identified intraoperatively, and repair techniques, including two-layer rectal wall closure and vesicourethral anastomosis, were recorded. Risk factors, such as prior pelvic surgery and high-risk pathological features, were also analyzed. Postoperative continence status at 12 months was evaluated using daily pad count, and erectile dysfunction was evaluated using the International Index of Erectile Function (IIEF-5) Results: RI was observed in 2.4% of patients (n = 9), and repairs were successfully completed intraoperatively in all cases. During multivariate analysis, the BMI was found to be protective against RI. Among RI patients, one patient developed a rectourethral fistula, which required reoperation and diversion colostomy; however, six months after the closure colostomy, the fistula persisted, and the patient suffered from severe incontinence. The postoperative 12-month IIEF-5 median score was 7. Conclusions: This study highlights the importance of early intraoperative detection and meticulous surgical repair of RI during RP. Diagnostic measures, such as pneumatic testing and rectal wall monitoring, can mitigate postoperative complications. Our findings contribute to a better understanding of RI management and underscore the importance of individualized surgical approaches for high-risk patients. Full article
(This article belongs to the Special Issue Advances in the Clinical Management of Genitourinary Tumors)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 505 KiB  
Review
The Role of Genomic Scores in the Management of Prostate Cancer Patients: A Comprehensive Narrative Review
by Alessandro Viti, Leonardo Quarta, Paolo Zaurito, Alfonso Santangelo, Andrea Cosenza, Francesco Barletta, Simone Scuderi, Armando Stabile, Vito Cucchiara, Francesco Montorsi, Giorgio Gandaglia and Alberto Briganti
Cancers 2025, 17(14), 2334; https://doi.org/10.3390/cancers17142334 - 14 Jul 2025
Viewed by 342
Abstract
Genomic score testing is increasingly being integrated into the management of prostate cancer (PCa) to overcome the limitations of traditional clinical and pathological parameters. Genomic tools will represent essential components of precision medicine, supporting risk stratification, therapeutic decision-making, and personalized screening strategies. Genomic [...] Read more.
Genomic score testing is increasingly being integrated into the management of prostate cancer (PCa) to overcome the limitations of traditional clinical and pathological parameters. Genomic tools will represent essential components of precision medicine, supporting risk stratification, therapeutic decision-making, and personalized screening strategies. Genomic score tests can be broadly classified into two main categories: polygenic risk scores (PRSs) and tumor-derived genomic classifiers (GCs). While not yet standard in routine practice, several international guidelines recommend their selective use when results are likely to impact clinical management. PRSs estimate an individual’s susceptibility to PCa based on the cumulative effect of multiple low-penetrance germline genetic variants. These scores show promise in enhancing early detection strategies and identifying men at higher genetic risk who may benefit from tailored screening protocols. Tumor-based GCs assays provide prognostic information that complements conventional clinical and pathological parameters, and are used to guide treatment decisions, including eligibility for active surveillance (AS) or adjuvant therapy after treatment of the primary tumor. This review summarizes and analyzes the current evidence on genomic testing in PCa, with a focus on the available assays, their clinical applications, and their predictive and prognostic value across the disease spectrum. When integrated with clinical and pathological parameters, these tools have the potential to significantly enhance personalized care and should be increasingly considered in routine clinical practice. Full article
(This article belongs to the Special Issue Advances in the Clinical Management of Genitourinary Tumors)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop